中新社北京1月17日电 (记者 欧阳开宇)中国食品药品检定研究院副院长王军志17日在北京表示，中国将参与主导生物制品国际标准的制修订。

China news agency Beijing on January 17 (Reporter OuYangKaiYu)China's food and drug test institute, vice President of the WangJunZhi 17 said in Beijing,China will participate in leading biological products international standard system revision.

　　王军志当天在国家食品药品监督管理局召开的新闻发布会上说，世界卫生组织年初正式批准中国食品药品检定研究院生物制品检定所成为其生物制品标准化和评价合作中心，这证明中国在生物制品领域的检验和质量保证能力以及技术水平已达国际标准。

WangJunZhi in the state food and drug administration, told a news conference,The world health organization official approval at the beginning of China's food and drug test institute of biological products shall be its biological product standardization and evaluation cooperation center,This proof in China in the field of biological products inspection and quality assurance ability and technical level has reached the international standard.

　　“这是全球第7个，也是发展中国家首个世卫组织生物制品标准化和评价合作中心。”王军志说。

"This is the seventh,In developing countries is also the first world health organization biological product standardization and evaluation cooperation center."WangJunZhi said.

　　此前，世卫组织在生物制品标准化和监管评价领域的6个合作中心，全部来自发达国家著名质量控制实验室，包括英国、日本、澳大利亚、美国和加拿大等国的相关机构。

after,The world health organization in the biological product standardization and regulation of the evaluation area of 6 cooperation center,All from the developed countries famous quality control laboratory,Including Britain/Japan/Australia/The United States and Canada and other countries of the relevant organizations.

　　王军志说，世卫组织生物制品技术标准的制修订和标准品的研制，长期以来由发达国家主导，他们通常根据本国企业的技术能力和需求制定相关技术标准，而中国作为世界上最大的疫苗生产国和使用国却只有有限的参与权，只能被动地参照相关国际技术标准。

WangJunZhi said,The world health organization biological products technical standard system and the development of the revised standard product,For a long time by the developed countries leading,They usually according to the domestic demand and the technical ability of the enterprise and make the relevant technical standards,China as the world's largest producer and vaccine use countries have only limited participation,Can only passively with reference to relevant international technical standard.

　　王军志表示，未来中国将参与主导生物制品标准的制修订，并参与主导国际生物制品标准品的制备研究，中国研发的生物技术药物走出国门参加国际竞争也将有重要的技术支撑。(完)

WangJunZhi said,The future China will participate in leading biological products standard system revision,And participate in the leading international biological products standard product preparation research,China r&d of biotech drugs out of the country to participate in the international competition will also have important technical support.(finish)